Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pacgen Life Science Corp.

www.pacgenbiopharm.com

Latest From Pacgen Life Science Corp.

Deals Shaping The Medical Industry, March 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January through February 2014.

BioPharmaceutical Medical Device

Execs On The Move, June 2013

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

BioPharmaceutical Medical Device

Ischemix names Robert DuFresne CEO

Ischemix, a US biotechnology company developing compounds to reduce and/or prevent cell and organ damage associated with ischaemia-reperfusion injury caused by cardiac surgery, heart attack and stenting procedures, has named Robert DuFresne chief executive officer. The company's former CEO, Dr Reinier Beeuwkes, will continue to serve as president and chairman. Mr DuFresne has more than 25 years' experience in the biopharmaceutical industry, having most recently worked as president and CEO of Pacgen Biopharmaceuticals. He has served on Ischemix's board of directors since May 2007, a role in which he will continue.

Cardiovascular Companies

Medigen and Pacgen call off merger

Pacgen Biopharmaceuticalsand Taiwan's Medigen Biotechnologyhave called off their planned merger next month, citing the expected cash cost of the transaction.

Taiwan
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Pacgen Biopharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Pacgen Life Science Corp.
  • Senior Management
  • Chung-Yu Wang, CEO
    Christina Yip, CFO
    Beverly Incledon, PhD, VP, R&D
    Joel Cheng, VP, Bus. Dev.
  • Contact Info
  • Pacgen Life Science Corp.
    Phone: (604) 436-4388
    701 West Georgia St., Ste. 1500
    Vancouver, V7Y 1C6
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register